Chloroeremomycin

Chloroeremomycin
Names
	Other names Chloroorienticin A, A82846B, LY264826
Identifiers
CAS Number	118395-73-6 ;
3D model (JSmol)	Interactive image ;
ChEBI	CHEBI:29556 ;
ChEMBL	ChEMBL1688951 ;
ChemSpider	391744 ;
KEGG	C12014 ;
PubChem CID	445806 ;
UNII	X47SLZ2K7D ;
	InChI InChI=1S/C73H88Cl2N10O26/c1-26(2)14-38(79-7)64(96)84-54-56(91)30-9-12-42(36(74)16-30)106-44-18-32-19-45(60(44)111-71-61(58(93)57(92)46(25-86)108-71)110-49-24-73(6,78)63(95)28(4)105-49)107-43-13-10-31(17-37(43)75)59(109-48-23-72(5,77)62(94)27(3)104-48)55-69(101)83-53(70(102)103)35-20-33(87)21-41(89)50(35)34-15-29(8-11-40(34)88)51(66(98)85-55)82-67(99)52(32)81-65(97)39(22-47(76)90)80-68(54)100/h8-13,15-21,26-28,38-39,46,48-49,51-59,61-63,71,79,86-89,91-95H,14,22-25,77-78H2,1-7H3,(H2,76,90)(H,80,100)(H,81,97)(H,82,99)(H,83,101)(H,84,96)(H,85,98)(H,102,103)/t27-,28-,38+,39-,46+,48-,49-,51+,52+,53-,54+,55-,56+,57+,58-,59+,61+,62-,63-,71-,72-,73-/m0/s1 Key: XJHXLMVKYIVZTE-LOALFDMRSA-N;
	SMILES CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)OC1CC(C(C(O1)C)O)(C)N)NC7=O)C(=O)O)O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O;
Properties
Chemical formula	C73H88Cl2N10O26
Molar mass	1592.45 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Last updated December 21, 2023

Chloroeremomycin is a member of the glycopeptide family of antibiotics, such as vancomycin.^[1] The molecule is a non-ribosomal polypeptide that has been glycosylated. It is composed of seven amino acids and three saccharide units. Although chloroeremomycin has never been in clinical phases, oritavancin, a semi-synthetic derivative of chloroeremomycin, has been investigated.

History

Chloroeremomycin was discovered by Eli Lilly in the 1980s. In the 1990s, researchers at Eli Lilly developed biphenyl-chloroeremomycin, now known as oritavancin, as a functionalized derivative of chloroeremomycin to combat rising antibacterial resistance to vancomycin.^[2] The chloroeremomycin gene cluster was sequenced by van Wageningen et al in 1998.^[3] After the publication, many groups expressed the genes and conducted experiments to understand how chloroeremomycin and, by extension, vancomycin are biosynthesized.^{[ citation needed ]}

Structure

Chloroeremomycin is composed of seven amino acids (three non-proteinogenic, and four proteinogenic) and three saccharide units. From N-terminus to C-terminus, the order is: Me-L-Leu, L-Tyr, D-Asn, D-4-hydroxyphenylglycine (HPG), L-HPG, D-Tyr, and D-3,5-dihydroxyphenylglycine (DHPG). When referring to specific amino acids, this article will reference the amino acid in the order it appears within the heptapeptide. Chloroeremomycin is glycosylated at aa4 with a Glc-(2→α1)-epivancosamine disaccharide and at aa6 with a D-BHT-(→α1)-epivancosamine saccharide.^{[ citation needed ]}

Some amino acids are modified prior to the completion of the heptapeptide (in cis) and some are modified after the heptapeptide is formed (in trans). During the synthesis of the heptapeptide, the stereocenters of aa3, aa4, aa6, and aa7 are changed from L to D. Both Tyr residues are hydroxylated and chlorinated after the amino acids have been incorporated to the growing polypeptide to form 4-chloro-β-hydroxytyrosine (BHT). The now-BHT residues are then crosslinked to the aa4 HPG through aryl-ether linkages. An aryl-aryl bond is formed between aa5 and aa7 at the aa5-C3 and aa7-C2 positions on the aromatic rings. Finally, the N-terminus Leu is methylated.^{[ citation needed ]}

In addition to the presence of D-amino acids, the molecule has atropisomer chemistry. The orientations of the chloro-substituted phenyl rings add another aspect of stereochemistry to the molecule.

Biosynthesis

Chloroeremomycin was found to be synthesized by Amycolatopsis orientalis.

Non-ribosomal peptide synthase

The non-ribosomal peptide synthase (NRPS) is encoded by three genes: CepA, CepB, and CepC. CepA links the first three amino acids; CepB adds the fourth to sixth amino acids; CepC adds the last amino acid and includes a thioesterase domain to release the heptapeptide from the NRPS complex.^[4] The growing peptide chain is passed through modules for each amino acid. The basic organization of each module is A-PCP-C. The A, or adenylation, region activates the domain's amino acid to allow transfer to the PCP, or peptide carrying protein, region. The activated amino acid is transferred to a cysteine residue in the PCP region, which anchors the amino acid and prepares the amino acid to be added to the polypeptide. The C, or condensation, region attaches the amino acid to the polypeptide. In addition, modules 2, 4, and 5 have E regions that epimerize (switch the stereochemistry) of the added amino acid to produce the correct configuration. Module 7, the last module, has an X and TE region. The X region is responsible for recruiting several of the tailoring enzymes that will perform the necessary reactions (halogenation, glycosylation, methylation, oxidative cross-linking, and hydroxylations) to produce chloroeremomycin.^[5] Finally, the TE, or thioesterase, region releases chloroeremomycin from the NRPS complex.

Post-peptide modifications

The modification required to biosynthesize mature chloroeremomycin include: oxidative cross-linking of aromatic rings, hydroxylation and chlorination of the two Tyr residues, methylation of Leu, and glycosylation at aa4 and aa6.^[3]

The oxidative crosslinks are catalyzed by enzymes OxyA-C. The glycosylations are catalyzed by enzymes GtfA-C (coded by Orf11-13 respectively). The chlorinations are performed by enzymes encoded by Orf10 and 18.^{[ citation needed ]}

Total synthesis

There is no reported total synthesis of chloroeremomycin, although there are several total syntheses of vancomycin. The structures of vancomycin and chloroeremomycin are very similar, differing only in the glycosylation sites. Vancomycin is glycosylated at aa4 with a (2-beta1)-Glc-vancosamine disaccharide. As mentioned above, chloroeremomycin is glycosylated at aa4 with a (2-beta1)-Glc-epivancosamine disaccharide and at aa6 with a beta1-epivancosamine saccharide.

Pharmacology and chemistry

Related Research Articles

Peptides are short chains of amino acids linked by peptide bonds. A polypeptide is a longer, continuous, unbranched peptide chain. Polypeptides which have a molecular mass of 10,000 Da or more are called proteins. Chains of fewer than twenty amino acids are called oligopeptides, and include dipeptides, tripeptides, and tetrapeptides.

A glycosidic bond or glycosidic linkage is a type of ether bond that joins a carbohydrate (sugar) molecule to another group, which may or may not be another carbohydrate.

<span class="mw-page-title-main">Vancomycin</span> Antibiotic medication

Vancomycin is a glycopeptide antibiotic medication used to treat a number of bacterial infections. It is used intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant Staphylococcus aureus. Blood levels may be measured to determine the correct dose. Vancomycin is also taken orally as a treatment for severe Clostridium difficile colitis. When taken orally it is poorly absorbed.

<span class="mw-page-title-main">Glycoprotein</span> Protein with oligosaccharide modifications

Glycoproteins are proteins which contain oligosaccharide chains covalently attached to amino acid side-chains. The carbohydrate is attached to the protein in a cotranslational or posttranslational modification. This process is known as glycosylation. Secreted extracellular proteins are often glycosylated.

Proteoglycans are proteins that are heavily glycosylated. The basic proteoglycan unit consists of a "core protein" with one or more covalently attached glycosaminoglycan (GAG) chain(s). The point of attachment is a serine (Ser) residue to which the glycosaminoglycan is joined through a tetrasaccharide bridge. The Ser residue is generally in the sequence -Ser-Gly-X-Gly-, although not every protein with this sequence has an attached glycosaminoglycan. The chains are long, linear carbohydrate polymers that are negatively charged under physiological conditions due to the occurrence of sulfate and uronic acid groups. Proteoglycans occur in connective tissue.

Teicoplanin is an antibiotic used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. It is a semisynthetic glycopeptide antibiotic with a spectrum of activity similar to vancomycin. Its mechanism of action is to inhibit bacterial cell wall synthesis.

Nonribosomal peptides (NRP) are a class of peptide secondary metabolites, usually produced by microorganisms like bacteria and fungi. Nonribosomal peptides are also found in higher organisms, such as nudibranchs, but are thought to be made by bacteria inside these organisms. While there exist a wide range of peptides that are not synthesized by ribosomes, the term nonribosomal peptide typically refers to a very specific set of these as discussed in this article.

<span class="mw-page-title-main">Glycopeptide antibiotic</span> Class of antibiotic drugs

Glycopeptide antibiotics are a class of drugs of microbial origin that are composed of glycosylated cyclic or polycyclic nonribosomal peptides. Significant glycopeptide antibiotics include the anti-infective antibiotics vancomycin, teicoplanin, telavancin, ramoplanin and decaplanin, corbomycin, complestatin and the antitumor antibiotic bleomycin. Vancomycin is used if infection with methicillin-resistant Staphylococcus aureus (MRSA) is suspected.

Daptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.

<span class="mw-page-title-main">Dihydroxyphenylglycine</span> Chemical compound

(S)-3,5-Dihydroxyphenylglycine or DHPG is a potent agonist of group I metabotropic glutamate receptors (mGluRs) mGluR1 and mGluR5.

Glycopeptides are peptides that contain carbohydrate moieties (glycans) covalently attached to the side chains of the amino acid residues that constitute the peptide.

Streptogramin A is a group of antibiotics within the larger family of antibiotics known as streptogramins. They are synthesized by the bacteria Streptomyces virginiae. The streptogramin family of antibiotics consists of two distinct groups: group A antibiotics contain a 23-membered unsaturated ring with lactone and peptide bonds while group B antibiotics are depsipeptides. While structurally different, these two groups of antibiotics act synergistically, providing greater antibiotic activity than the combined activity of the separate components. These antibiotics have until recently been commercially manufactured as feed additives in agriculture, although today there is increased interest in their ability to combat antibiotic-resistant bacteria, particularly vancomycin-resistant bacteria.

Streptogramin B is a subgroup of the streptogramin antibiotics family. These natural products are cyclic hexa- or hepta depsipeptides produced by various members of the genus of bacteria Streptomyces. Many of the members of the streptogramins reported in the literature have the same structure and different names; for example, pristinamycin IA = vernamycin Bα = mikamycin B = osteogrycin B.

<span class="mw-page-title-main">Valorphin</span> Chemical compound

Valorphin, also known as VV-hemorphin-5, is a naturally occurring, endogenous opioid heptapeptide of the hemorphin family with the amino acid sequence H-Val-Val-Tyr-Pro-Trp-Thr-Gln-OH (VVYPWTQ). It is produced in the body via proteolyic cleavage of residues 33-39 of the β-chain of hemoglobin. Valorphin binds preferentially to the μ-opioid receptor and produces effects such as analgesia and self-administration in animals. It also possesses cytotoxic and antiproliferative properties against tumor cells, the mediation of which, because they are reversed by naloxone, appears to be dependent on the opioid receptors.

Protein O-GlcNAc transferase also known as OGT or O-linked N-acetylglucosaminyltransferase is an enzyme that in humans is encoded by the OGT gene. OGT catalyzes the addition of the O-GlcNAc post-translational modification to proteins.

Pluramycin A is an antibiotic/anticancer compound that inhibits nucleic acid biosynthesis. The pluramycin family of natural products are an important group of complex C-aryl glycoside antibiotics that possess the tetracyclic 4H-anthra[1,2-b]pyran-4,7,12-trione moiety A–D as an aromatic core. The D-ring is adorned with two deoxyaminosugars that are appended by C-aryl glycosidic linkages. The E-ring sugar is angolosamine, a carbohydrate that is also found in the antibiotic angolamycin. The F-ring sugar is the N,N-dimethyl derivative of vancosamine, which is the sugar found in the glycopeptide antibiotic vancomycin.

Bottromycin is a macrocyclic peptide with antibiotic activity. It was first discovered in 1957 as a natural product isolated from Streptomyces bottropensis. It has been shown to inhibit methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) among other Gram-positive bacteria and mycoplasma. Bottromycin is structurally distinct from both vancomycin, a glycopeptide antibiotic, and methicillin, a beta-lactam antibiotic.

Lipid II is a precursor molecule in the synthesis of the cell wall of bacteria. It is a peptidoglycan, which is amphipathic and named for its bactoprenol hydrocarbon chain, which acts as a lipid anchor, embedding itself in the bacterial cell membrane. Lipid II must translocate across the cell membrane to deliver and incorporate its disaccharide-pentapeptide "building block" into the peptidoglycan mesh. Lipid II is the target of several antibiotics.

Vancosamines are aminosugars that are a part of vancomycin and other molecules within the vancomycin family of antibiotics. Vancosamine synthesis is encoded by the vancomycin (vps) biosynthetic cluster. Epivancosamine, a closely related aminosugar, is encoded by the chloroeremomycin (cep) biosynthetic cluster.

4-Hydroxyphenylglycine (HPG) is a non-proteogenic amino acid found in vancomycin and related glycopeptides. HPG is synthesized from the shikimic acid pathway and requires four enzymes to synthesize: Both L- and D-HPG are used in the vancomycin class of antibiotics. Tyrosine, a similar amino acid, differs by a methylene group (CH2) between the aromatic ring and the alpha carbon.

References

↑ Wright, Andrew G. McArthur, Gerard D. "The Comprehensive Antibiotic Resistance Database". card.mcmaster.ca. Retrieved 2018-06-12.{{cite web}}: CS1 maint: multiple names: authors list (link)
↑ Sharman, G. J., Try, A. C., Dancer, R. J., Cho, Y. R., Staroske, T., Bardsley, B., Maguire, A. J., Cooper, M. A., O'Brien, D. P., Williams, D. H. "The Roles of Dimerization and Membrane Anchoring in Activity of Glycopeptide Antibiotics against Vancomycin-Resistant Bacteria." J. Am. Chem. Soc.1997, 119, 12041-12047.
1 2 van Wageningen, A. M. A., Kirkpatrick, P. N., Williams, D. H., Harris, B. R., Kershaw, J. K., Lennard, N. J., Jones, M., Jones, S. J. M., Solenberg, P. J. "Sequencing and analysis of genes involved in the biosynthesis of a vancomycin group antibiotic." Chemistry & Biology, 1997, 5, 155-162.
↑ Yim, G., Thaker, M. N., Koteva, K., Wright, G. "Glycopeptide antibiotic biosynthesis." The Journal of Antibiotics, 2017, 67, 31-41.
↑ Haslinger, K., Peschke, M., Brieke, C., Maximowitsch. E., Cryle, M. J. "X-domain of peptide synthetases recruits oxygenases crucial for glycopeptide biosynthesis." Nature, 2015, 521, 105-110.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Wright, Andrew G. McArthur, Gerard D. "The Comprehensive Antibiotic Resistance Database". card.mcmaster.ca. Retrieved 2018-06-12.{{cite web}}: CS1 maint: multiple names: authors list (link)

[2] Sharman, G. J., Try, A. C., Dancer, R. J., Cho, Y. R., Staroske, T., Bardsley, B., Maguire, A. J., Cooper, M. A., O'Brien, D. P., Williams, D. H. "The Roles of Dimerization and Membrane Anchoring in Activity of Glycopeptide Antibiotics against Vancomycin-Resistant Bacteria." J. Am. Chem. Soc.1997, 119, 12041-12047.

[van_Wageningen-3] 1 2 van Wageningen, A. M. A., Kirkpatrick, P. N., Williams, D. H., Harris, B. R., Kershaw, J. K., Lennard, N. J., Jones, M., Jones, S. J. M., Solenberg, P. J. "Sequencing and analysis of genes involved in the biosynthesis of a vancomycin group antibiotic." Chemistry & Biology, 1997, 5, 155-162.

[4] Yim, G., Thaker, M. N., Koteva, K., Wright, G. "Glycopeptide antibiotic biosynthesis." The Journal of Antibiotics, 2017, 67, 31-41.

[5] Haslinger, K., Peschke, M., Brieke, C., Maximowitsch. E., Cryle, M. J. "X-domain of peptide synthetases recruits oxygenases crucial for glycopeptide biosynthesis." Nature, 2015, 521, 105-110.

[1]

[2]

[3]

[4]

[5]